Identifying digital pathology imaging based biomarkers of checkpoint inhibitor response in non-small cell lung cancer.
Sushant Patkar(National Institutes of Health), Tamara Jamaspishvili(SUNY Upstate Medical University), Rahul Rajendran(SUNY Upstate Medical University), Stephanie A. Harmon(National Institutes of Health), Barış Türkbey(National Institutes of Health), Peter L. Choyke(National Cancer Institute), Alina Basnet(SUNY Upstate Medical University), Alex Chen(National Institutes of Health)
Cited by 1
Related Papers
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
|Nature Genetics|1997|1.5k
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
|JAMA Oncology|2015|309
Characteristics of Congenital Hepatic Fibrosis in a Large Cohort of Patients With Autosomal Recessive Polycystic Kidney Disease
|Gastroenterology|2012|179
Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
|Nature Communications|2020|156